Latest News for AVCNF
Strategic investment by pharmaceutical executive and life sciences investor Michael Porter Strategic investment by pharmaceutical executive and life sciences investor Michael Porter
Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured
Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats
TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as…
FORT LAUDERDALE, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for AVCNF.
Senate Trading
No Senate trades found for AVCNF.
U.S. House Trading
No House trades found for AVCNF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.